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1   Introduction 
1.1   Formation of brain metastases 
Brain metastases of malignant tumors have a very poor prognosis and are frequent 
complications for cancer patients. Only in the United States, about 170,000 metastatic brain 
tumors are diagnosed annually (Platta et al, 2010), whereas primary brain tumors represent 
17,000 new cases/year. During metastasis formation, tumor cells successfully infiltrating the 
brain parenchyma overcome several obstacles, including survival in the circulation (Lorger & 
Felding-Habermann, 2010), extravasation through brain capillaries and resisting deleterious 
signals of the reactive brain stroma (Valiente et al, 2014). However, cancer cells able to 
migrate into and to survive in the brain will benefit of a supportive and protective 
microenvironment, including the dense vasculature with the opportunity of vessel co-option 
(Bugyik et al, 2011) and chemoprotection mediated by astrocytes and endothelial cells (Kim 
et al, 2014). As a consequence, brain metastases have a poor prognosis. The survival of 
patients with central nervous system (CNS) metastases is low: the median survival time is 4-6 
months, and only 20-40% of patients are alive at 1 year after the diagnosis (Pestalozzi, 2009). 
The most common cancers that spread to the brain are lung cancer (40-50% of brain 
metastases originate from lung carcinomas), breast cancer (15-25%) and melanoma (5-20%) 
(Wen et al, 2011).  
Breast cancer is the second most common type of cancer, the most frequent in women 
and worldwide causes more than half a million deaths annually. Usually breast cancer either 
begins in the cells of the lobules or in the ducts, these cancer types are carcinomas. Less 
commonly, breast cancer can begin in the stromal tissues, these cancer types are sarcomas. 
Within carcinomas, there are many different types of breast cancer. In situ carcinoma is "pre-
invasive" carcinoma that has not yet invaded the breast tissue. Invasive carcinomas have the 
potential to spread to other sites of the body, including the brain. 
Breast cancer metastases to the CNS include the clinically distinct situations of 
multiple brain metastases (78%), solitary brain metastases (14%) and leptomeningeal 
metastases (8%) (Pestalozzi, 2009). CNS metastases occur in 10-16% of stage IV patients, 
while they are found in 30% of patients in autopsy series (Pestalozzi, 2009). In most cases, 
brain metastases represent a late relapse in breast cancer patients who already have liver, lung 
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or bone involvement. Previous studies have identified several risk factors of brain metastases. 
Especially, estrogen receptor (ER) negative status is associated with high incidence of brain 
metastases. Overexpression of epidermal growth factor receptor 2 (EGFR2, also known as 
HER2) is reported as another risk factor. Some other factors were also reported to associate 
with brain metastases of breast cancer: p53 positivity, high EGFR expression, lower BCL-2 
expression and expression of basal CK5/6 (cytokeratin 5/6) (Chang et al, 2003; Hicks et al, 
2006; Stemmler et al, 2006). Triple-negative breast cancers, which are very aggressive tumors, 
are characterized by lack of ER, of progesterone receptor (PR), and of HER2 overexpression. 
They are typically associated with poor prognosis and give brain metastases with high 
frequency. This type of breast cancer has only partial response to chemotherapy and to 
targeted therapies (Cetin & Topcul, 2014). 
Melanoma is a malignant tumor which develops from melanocytes. This is one of the 
most aggressive types of skin cancer. Melanomas are usually caused by DNA damage 
resulting from exposure to ultraviolet (UV) light from the sun, but genetics also plays an 
important role. A number of rare mutations, which often run in families, greatly increase 
melanoma susceptibility. One class of mutations affects the gene CDKN2A (cyclin-dependent 
kinase inhibitor 2A), which acts as tumor suppressor. MC1R (melanocortin 1 receptor) gene 
mutation also increases the risk. Proteins involved in the MAPK (mitogen activated protein 
kinase) pathway that regulate transcription of genes involved in cell proliferation and survival 
also take part in melanoma development. Mutations in NRAS and BRAF, two proteins in the 
MAPK pathway, are found in 20% and 60% of melanomas, respectively. The most commonly 
seen BRAF mutation is a substitution of valine with glutamate (V600E). It has also been 
demostrated that upregulation of the PI3K (phosphoinositide 3-kinase) pathway 
(PTEN/phosphatase and tensin homolog deletion or Akt activation) and subsequent inhibition 
of apoptosis also increases the risk of melanoma development (Lee et al, 2014). 
Based on the depth of the primary tumor and on the distance the cancer has spread to, 
melanoma is divided into four stages. Breslow thickness is the depth of the tumor mass 
calculated perpendicularly from the skin surface (in mm) 
(http://www.americanskin.org/resource/melanoma.php). In situ melanomas have a better 
prognosis after surgical excision with a sufficient surgical margin. Invasive melanomas are far 
more serious. Melanoma can spread to the liver, bones, abdomen or distant lymph nodes, and 
these tumor cells have an unexpectedly high affinity to the brain. This is partly due to the fact 
that the neural environment plays a key role in the protection and growth of melanoma cells, 
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which are of ectodermal origin, similar to the CNS. 
Melanoma brain metastases are diagnosed in 40-50% of the patients, which, after 
autopsy, increases with an additional 30-40% (Fidler et al, 1999). Melanoma causes 4% of all 
skin cancers but is responsible for 74% of skin cancer deaths, and this is mainly due to the 
high incidence of brain metastases. Of melanoma brain metastases 49% are intraparenchymal, 
22% are leptomeningeal and 32% are dural (Fidler et al, 1999). The number of diagnosed 
melanoma cases is constantly increasing (Douglas & Margolin, 2002). Mean survival from 
diagnosis of melanoma brain metastasis varies from 2 to 16 months, while the mean 1-year 
survival is estimated to be only about 20% (Fidler et al, 1999). 
Approximately 60% of patients with brain metastases have subacute symptoms. 
Symptoms are usually related to the location of the tumor and may include the following: 
headache, seizure, nausea, vomiting, nuchal rigidity, photophobia, cognitive dysfunction and 
motor dysfunction (Saha et al, 2013). Longer survival, improved quality of life and 
stabilization of neurocognitive function for patients with brain metastasis is the goal of 
treatments. Unfortunately not even these goals are completely met by current therapies, which 
include surgery, whole-brain radiation therapy, chemotherapy, stereotactic radiosurgery and 
targeted therapies (Leone & Leone, 2015). In most tumor types chemotherapy shows limited 
or no activity in brain metastases, because many systemically used chemotherapeutic agents 
do not cross the blood-brain barrier (BBB), and therefore do not reach a therapeutically 
relevant concentration in the brain metastatic lesion. Others may transiently weaken the BBB 
(Blecharz et al, 2015). Trastuzumab – a monoclonal antibody against HER2, approved for the 
first line treatment of HER2 positive breast cancers – is not able to cross the BBB, thus it is 
inefficient in inhibiting the growth of brain metastatic lesions of breast cancer. Some new 
chemotherpeutic agents have been developed which can pass the BBB and target tumor cells, 
e.g. temozolomide, an alkylating agent, which is a basic compound in the therapy of brain 
metastases. According to clinical studies, the combination of temozolomide with 
radiotheraphy or with other cytotoxic agents shows a few months prolonged median survival 
(Owonikoko et al, 2014). However, these results are far from the final goal of total remission; 
therefore, it is necessary to further optimize current methods. In the treatment of melanoma 
one of the most important targeted therapeutic agents is vemurafenib, which is an inhibitor of 
V600E BRAF mutation in metastatic melanoma, and is often used in combination with radio- 
and immunotherapy (Owonikoko et al, 2014). It has been recently shown that vemurafenib 
can be safely and effectively used in patients with brain metastatic melanoma (Dummer et al, 
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2014). However, the responses are frequently unsatisfactory, rangig from substantial side-
effects and toxicity to no impact of the treatment on the metastatic lesion. Therefore, 
prevention of the formation of brain lesions would be of great clinical benefit. 
Since the CNS parenchyma lacks a lymphatic circulation, the only possibility for 
cancer cells to reach the brain is via the blood stream. Brain metastases can be formed both in 
the parenchyma and the meninges. Leptomeningeal metastases resulting from solid tumors 
occur late and usually coexist with CNS parenchymal disease. Metastatic cells invading the 
CNS parenchyma, however, have to pass the BBB. During transmigration through the BBB, 
arrest of tumor cells was found to take place at the level of capillaries and postcapillary 
venules, where the diameter of the vessels is comparable to those of the metastatic cells, 
predominantly at vessel branches (Kienast et al, 2010). 
1.2   The blood-brain barrier 
1.2.1   Cellular structure of the blood-brain barrier 
The BBB is located at the level of cerebral capillaries in the forefront of the defense 
line of the CNS and restricts the free movement of solutes and cellular elements between the 
systemic circulation and neuronal tissue. The most important cellular elements of the BBB are 
endothelial cells, astrocytes and pericytes, which together with the extracellular matrix and 
neurons form the neurovascular unit (Figure 1A). 
Endothelial cells lining brain capillaries are thin, flat cells interconnected by tight 
junctions (TJs) (Brightman & Reese, 1969) and characterized by a high number of 
mitochondria (Oldendorf et al, 1977) and low number of caveolae (Nag, 2003). The contact 
region of brain endothelial cells is usually overlapping, and the border between the apical and 
basolateral cell membranes is interconnected by a continuous line of tight junctions. This 
limits the free transport of different solutes and cellular elements between adjacent cells. 
Cerebral endothelial cells (CECs) share common features with other endothelia (presence of 
factor VIII, high alkaline phosphatase and γ-glutamyl transpeptidase activity, uptake of 
acetylated-low density lipoprotein) and epithelia as well (high transendothelial electrical 
resistance (TEER), continuous line of TJs, low level of pinocytosis), these latter being 
indispensable for the barrier function. 
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Figure 1. Schematic diagram of the blood-brain barrier. The core anatomical structure of the BBB is 
formed by cerebral endothelial cells, which share common basal membrane with pericytes, and are 
covered by astrocytic endfeet (A). Endothelial cells are interconnected by a continuous line of tight 
junctions. The inset illustrates the molecular structure of the junctional complex (B). ABC transporters 
and SLC transporters in brain endothelial cells (C). 
 
Endothelial cells are framed by a basal membrane, which consists mainly of collagen 
IV, fibronectin, proteoglycans and laminin. The extracellular matrix (ECM) participates in the 
maintanence of endothelial barrier integrity. Disruption of the basal membrane might lead to 
alterations affecting the junctional proteins of the BBB (Hawkins & Davis, 2005). The integ-
rin β1-mediated attachment of endothelial cells to the basement membrane is critical for clau-
din-5 stabilisation (Osada et al, 2011). Furthermore, during brain metastasis formation the 
basal membrane is involved in the survival of tumor cells (Carbonell et al, 2009). 
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Pericytes are located in the duplication of the basement membrane, in close contact 
with endothelial cells. Even gap junctions have been described between the two cell types 
(Cuevas et al, 1984). Pericytes are contractile cells able to synthesize a plethora of 
biologically active substances. Although the exact function of pericytes in the formation and 
function of the BBB is insufficiently understood, they can participate in the regulation of 
blood flow, endothelial proliferation, angiogenesis or inflammatory processes. Absence of 
pericytes leads to endothelial hyperplasia, abnormal vasculogenesis (Hellström et al, 2001) 
and increased BBB permeability (Armulik et al, 2010). Pericyte-endothelial cell interactions 
were found to be critical in the regulation of the BBB during development (Daneman et al, 
2010). 
Astrocytes play a crucial role in the induction of barrier properties of CECs (Abbott et 
al, 2006; Haseloff et al, 2005; Krizbai et al, 2012). Astrocytic endfeet nearly completely 
ensheath the capillary walls, thereby covering not only endothelial cells, but also the 
intimately associated pericytes (Kacem et al, 1998). The coverage is not complete, allowing a 
direct contact of nerve endings with the basal membrane (Cohen et al, 1997; Paspalas & 
Papadopoulos, 1996). Astrocytic endfeet express a high level of several specific proteins at 
their capillary side, like glucose transporter 1, P-glycoprotein (P-gp), aquaporin-4, connexin-
43 and Kir 4.1 K+ channel. Astrocytes have an indispensable role in the maintenance of BBB 
properties of CECs. 
On the other hand, astrocytes have a protective role for brain metastases. Reactive 
astrocytes immediately localize to individual breast cancer cells even before extravasation and 
continue to associate with metastatic cells during the transmigration process and throughout 
the growth of the lesions (Lorger & Felding-Habermann, 2010). Moreover, astrocytes secrete 
soluble factors that stimulate the proliferation of tumor cells in the brain microenvironment. 
In this respect, neurotrophins have a special importance in supporting the growth of 
melanoma cells (Menter et al, 1995). Astrocytes have been shown to protect tumor cells 
through gap junctional communication (Lin et al, 2010), upregulation of survival genes (Kim 
et al, 2011) and secretion of soluble factors like inflammatory cytokines (Seike et al, 2011). 
In the brain distinct immune cells interact with the BBB. The most frequent CNS 
innate immune cells are microglia cells (Spindler & Hsu, 2012). They are localised in 
physical association with the brain capillaries and participate in angiogenic processes. 
Microglia cells influence BBB function in health and disease, but it is not completely 
understood how. Some in vitro co-culture experiments demonstrated influence of microglia 
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activation on barrier disturbances though modifications of TJ proteins (Nishioku et al, 2010; 
Sumi et al, 2010). 
1.2.2   Functions of the blood-brain barrier 
The main function of the BBB is to maintain the homeostasis of the CNS and to 
protect the brain from harmful compounds coming from the systemic circulation. The BBB 
has dual role, operates both as a barrier and as a carrier too. This latter function refers to the 
transport of nutrients to and removal of metabolites from the brain, and is mainly assured by 
solute-like carrier (SLC) transporters. 
Transport across the brain endothelium is strictly limited through a four-fold defense 
line (Wilhelm et al, 2011): the paracellular barrier (represented by interendothelial junctions); 
the transcellular barrier (assured by the low level of endocytosis and transcytosis); the 
enzymatic barrier (including acetylcholinesterase, alkaline phosphatase, γ-glutamyl 
transpeptidase, monoamine oxidases and drug metabolizing enzymes); and the efflux 
transporters (ABC-B1, -C1, -C4, -C5 and -G2). Small gaseous molecules, such as O2 and CO2, 
can freely diffuse through the lipid membranes, and this is also a route of entry for small 
lipophilic agents, including barbiturates, nicotine and ethanol. However, specific blood-to-
brain influx transport systems exist to supply nutrients, like glucose, amino acids and 
nucleotides, which cannot freely diffuse to the brain. Endothelial cells also express several 
ABC (ATP-binding cassette) transporters, which are mainly efflux transpoters (Figure 1C). 
The main role of the ABC transporters in the CNS is to work as active pumps 
consuming ATP and transporting a wide range of lipid-soluble compounds out of the brain 
capillary endothelium and the CNS. These transporters remove from the brain potentially 
neurotoxic endogenous or xenobiotic molecules and carry out a vital neuroprotective and 
detoxifying function (Abbott et al, 2010). In addition, certain efflux transporters are able to 
pump out chemotherapeutic agents as well; therefore, they decrease the effectiveness of 
chemotherapy. As a consequence, ABC transporters play a crucial role in the development of 
multidrug resistance (Löscher & Potschka, 2005). 
Integrity of the BBB has been reported to be disturbed in several disorders including 
cerebral ischemia, inflammation and brain tumors. Moreover, during inflammation and 
metastasis formation, the BBB is actively involved in the transmigration of leukocytes and 
tumor cells. 
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1.2.3   Molecular structure of the tight junctions (TJs) 
The paracellular permeability is mainly regulated by the TJs between endothelial cells 
(Figure 1B). Key components of the TJs are the transmembrane proteins, which form three 
protein families. These are the four transmembrane proteins (occludin, claudins, 
tricellulin/marvelD2, marvelD3), which are perhaps the most important from the point of 
view of paracellular permeability; molecules belonging to the immunoglobulin superfamily 
(JAM-Junctional adhesion molecule, CAR-Coxsackie and adenovirus receptor, ESAM-
Endothelial cell-selective adhesion molecule); and non-immunoglobulin-like molecules with a 
single transmembrane domain (CRB3-Crumbs homolog 3; Bves-Blood vessel epicardial 
substance). Best characterized in CECs are occludin, claudins and JAMs (Bauer et al, 2011). 
Occludin, the first identified transmembrane TJ protein (Furuse et al, 1993), is a 
65 kDa molecule. It is characterized by four transmembrane regions, two extracellular loops, 
a shorter N-terminal and a longer C-terminal cytoplasmic domain. The two extracellular loops 
are rich in tyrosine and glycine, playing a role in sealing the junctions (Lacaz-Vieira et al, 
1999; Wong & Gumbiner, 1997), while the C-terminal region is important in the interaction 
with other junctional proteins. 
Claudins, first described by Furuse et al. (Furuse et al, 1998), are small proteins (20-
27 kDa), which show a similar membrane topology to occludin; however, there is no 
sequence homology between them. Interactions of claudins are largely determined by the C-
terminal intracellular region, which contains PDZ (Psd95/Discs large 1/Zonula Occludens) 
binding domains. Furthermore, claudins are able to form homophylic interactions as well 
needed for the formation of TJ strands (Piontek et al, 2008). The principal claudin in brain 
endothelial cells is claudin-5, but other claudins (especially claudin-1, -3 and -12) have also 
been detected (Ohtsuki et al, 2008). The exact role of individual claudins is not known; 
absence of claudin-5 leads to a selective opening of the BBB to molecules smaller than 
800 Da (Nitta et al, 2003). 
Junctional adhesion molecules (JAMs) are single-span molecules belonging to the 
immunoglobulin superfamily, characterized by homophilic binding and two extracellular 
loops, first described by Martin-Padura et al. (Martìn-Padura et al, 1998). Brain endothelial 
cells express mainly JAM-1 (JAM-A) and JAM-3 (JAM-B) (Aurrand-Lions et al, 2001), but 
also JAM-C. They are involved in the extravasation of leukocytes. Endothelial cells also 
express ESAM, another immunoglobulin-like molecule localized to the TJs. JAM-C and 
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ESAM have been shown to promote melanoma lung metastasis formation (Cangara et al, 
2010; Langer et al, 2011). 
Zonula Occludens (ZO) proteins are peripheral proteins of TJs. There are three 
members of the zonula occludens family: ZO-1 (Stevenson et al, 1986), ZO-2 (Gumbiner et al, 
1991) and ZO-3 (Haskins et al, 1998). Common structural features of the ZO family include 
three PDZ domains in the N-terminal region, a SH3 (Src homology 3) domain and an 
enzymatically inactive GUK (guanylate kinase) domain. ZO proteins are important scaffold 
proteins, but are essential in signaling processes as well (Balda & Matter, 2000; Bauer et al, 
2011; Traweger et al, 2003). 
1.3   Interaction of tumor cells with the blood-brain barrier 
1.3.1   Transmigration routes 
Great amount of data is available regarding motility and migration of cancer cells, but 
information about the mechanisms involved in the migration of cancer cells across endothelial 
barriers is limited. Even less is known about the transmigration of tumor cells through the 
BBB. The process of transendothelial migration has been intensively studied using 
leukocytes. Although the steps of transmigration (rolling, adhesion and 
transmigration/diapedesis) may show some similarities, due to different physiological, 
molecular and mechanical characteristics of immune and metastatic cells, there may be 
significant differences (Strell & Entschladen, 2008). 
Transendothelial migration of cells can occur by two routes: the paracellular pathway 
(through the interendothelial junctions between endothelial cells) and the transcellular one 
(through single endothelial cells). Leukocytes are able to use both routes during their 
migration through peripheral and brain endothelia as well (Carman, 2009; Dejana, 2006; 
Reijerkerk et al, 2006; Wolburg et al, 2005). Paracellular transmigration of metastatic cells is 
possible only with the involvement of endothelial TJs and junctional proteins. Using an in 
vitro system, we have previously observed that melanoma cells damaged the integrity of the 
brain endothelial monolayer and decreased the transendothelial electrical resistance (TEER) 
which is a widely used indicator of junctional integrity (Fazakas et al, 2011). The mechanisms 
by which metastatic cells are able to disrupt TJs are incompletely understood; however, 
proteolytic processes probably play an important role. It is less known, whether breast cancer 
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cells are able to disrupt the TJs or migrate preferentially transcellularly. So far, transcellular 
migration of tumor cells has only been described in the case of intravasation of breast cancer 
cells into an artificial vascular network prepared from calf pulmonary artery endothelial cells 
(Khuon et al, 2010) and migration through umbilical cord endothelial cells (Arvanitis et al, 
2014). However, no data on the transmigration pathway of breast cancer cells through BBB 
endothelial cells exist. 
1.3.2   Molecular mechanisms involved in the extravasation of tumor cells 
through the blood-brain barrier 
Mechanisms of extravasation of tumor cells through the BBB are largely 
uncharacterized. According to our current knowledge, both metastatic and endothelial cells 
actively participate in this process by modulating the expression of surface molecules, 
secretion of soluble factors and activation of diverse signaling pathways. 
Attachment of tumor cells to the endothelium depends on the expression of adhesion 
molecules. Cancer cells, similar to leukocytes, express selectin ligands, which may play an 
important role in their adhesion to CECs. Selectin-dependent mechanisms are also important 
in the interaction of tumor cells with platelets and leukocytes, which facilitates attachment of 
tumor cells to the vessel wall. Moreover, heparin – which inhibits not only coagulation, but 
selectin-mediated interactions as well – was shown to inhibit adhesion of melanoma cells to 
brain endothelial cells (Fazakas et al, 2011) and to delay melanoma brain metastasis formation 
(Maraveyas et al, 2010). In addition, several integrins were shown to be involved in cancer 
progression, metastasis formation, transendothelial migration of tumor cells and angiogenesis 
in different metastatic sites. Activation of integrin αvβ3 was observed to support efficient 
brain metastatic growth of breast cancer cells through continuous upregulation of VEGF 
(vascular endothelial growth factor), without influencing the growth of primary lesions 
(Lorger et al, 2009). Cadherin dysfunction may also be involved in tumor progression and 
metastasis formation, e.g. metastatic brain tumors were shown to express high levels of E-
cadherin (Shabani et al, 2003). Transendothelial migration of melanoma cells through human 
lung microvascular endothelial cells has been shown to involve N-cadherin-mediated 
adhesion (Qi et al, 2005). A similar mechanism is possible in the case of brain endothelial 
cells as well. 
Different proteolytic enzymes have also been implicated in brain metastasis formation 
and migration of tumor cells through the BBB, including matrix metalloproteinases (MMPs), 
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serine proteases and heparanase. Tumor cell-secreted MMPs might have special importance, 
because TJ proteins can be targets of MMP degradation. According to literature data, MMP-2, 
MMP-3 and MMP-9 are implicated in the development of breast cancer brain metastases 
(Mendes et al, 2005). In addition, heparanase is considered a critical molecular determinant of 
brain metastasis in melanoma (Roy & Marchetti, 2009) and breast cancer (Zhang et al, 2010) 
as well. According to our previous results, during transmigration through the brain 
endothelium melanoma cells produce and release large amounts of gelatinolytic serine 
proteases, including seprase (Fazakas et al, 2011). These proteases facilitate the 
transendothelial migration of tumor cells. 
1.3.3   Signaling pathways involved in the extravasation 
Several signaling pathways (Rho and Rac signaling, the PI3K-Akt-PTEN pathway, 
MAPK signaling, Src signaling), alone or in combination, can underlie the extravasation 
process. Understanding the role of pathways activated either in tumor cells or in endothelial 
cells will help to identify molecular targets for cancer therapy. In our investigations we 
focused on the role of Rac, Rho/ROCK and PI3K signaling in the migration of tumor cells 
through the BBB. 
1.3.3.1   Role of Rho/ROCK and Rac signaling in the interaction of tumor cells 
with the BBB 
During invasion of tissues and migration through vessel walls and ECM components, 
metastasizing tumor cells require increased motility, which is dependent on the remodeling of 
the cytoskeleton. In this respect, members of the Rho family small GTPases were shown to 
have an indispensable role by regulating the two major modes of tumor cell movement, 
characterized by mesenchymal and amoeboid phenotype. The mesenchymal type of tumor 
cell movement requires elevated Rac1 activation and reduced Rho/ROCK signaling and is 
characterized by elongated cell morphology, formation of large membrane protrusions and 
dependence on integrins and extracellular proteolysis (Figure 2A). On the other hand, the 
amoeboid migration type mimics movement of leukocytes, with a rounded morphology and 
generation of Rho/ROCK-dependent actomyosin contractile forces (Sahai & Marshall, 2003; 
Sanz-Moreno et al, 2008; Wolf et al, 2003). These two types of movement are 
interconvertible and depend on the environment the cancer cells are move in (Symons & 
Segall, 2009). 
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Figure 2. Schematic representation of the two types of movement of cancer cells and signaling pathways 
implicated. Characterization of the amoeboid and mesenchymal types of cancer cell movement (A). 
Rho/ROCK and Rac signaling in the amoeboid and mesenchymal phenotypes (B). PI3K/Akt/mTor 
signaling and PI3K/P-Rex1/Rac signaling in breast cancer cells (C). 
 
The activity of Rho family GTPases is controlled by activators, guanine nucleotide 
A 
B 
C 
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exchange factors (GEFS) and inactivators, GTPase accelerating proteins (GAPs). Rac 
activation is mediated through the adaptor protein NEDD9 and the Rac GEF DOCK3, which 
drive mesenchymal movement and suppress amoeboid movement through the Rac effector 
WAVE2. In amoeboid movement a Rac GAP, ARHGAP22 suppresses the mesenchymal 
movement through inactivation of Rac (Sanz-Moreno & Marshall, 2009) (Figure 2B). 
Our previous results indicated that during transmigration through the brain 
endothelium, melanoma cells favor the mesenchymal type of cell movement. By inhibiting 
Rho/ROCK signaling, and therefore triggering the mesenchymal phenotype, we observed a 
significant increase in the number of transmigrated melanoma cells through brain endothelial 
monolayers. The question whether tumor cells prefer Rho/ROCK or Rac-dependent 
transendothelial migration is of clinical importance, since inhibitors of both Rho/ROCK (e.g. 
fasudil) and Rac pathways (Wertheimer et al, 2012) are emerging as potential therapeutic 
agents. 
1.3.3.2   Role of the PI3K signaling in the interaction of tumor cells with the 
BBB 
The pathway most frequently altered in human cancer is the PI3K signaling pathway. 
Genes encoding proteins in this pathway are mutated in more than 70% of breast cancers. 
Therefore, several potential therapeutic agents targeting nearly every aspect of this pathway 
are under development, clinical or preclinical assessment (http://am.asco.org/exploring-
pathway-despite-lukewarm-clinical-benefit-pi3k-inhibitors-optimism-remains-regarding). 
Class IA PI3Ks phosphorylate phosphatidylinositol (4,5)-bisphosphate (PIP2) in the 
inner side of the plasma membrane and produce phosphatidylinositol (3,4,5)-trisphosphate 
(PIP3). This activity is directly opposed by the tumor suppressor PTEN (phosphatase and 
tensin homolog). Akt/mTOR has canonically been regarded as the primary downstream 
pathway of PI3K, regulating cell growth, proliferation, survival and motility of cancer cells. 
However, PI3K regulates other pathways as well, e.g. the Rac activator PIP3-
dependent Rac exchange factor 1 (P-Rex1) (Figure 2C). Levels of P-Rex1 correlate with PI3K 
activation. P-Rex1 creates a positive feedback loop to activate PI3K/Akt and promotes 
viability of breast cancer cells (Dillon et al, 2015). Therefore, PI3K signaling may also be 
involved in the regulation of the amoeboid vs. mesenchymal type of cancer cell movement. 
In a recent study, a novel inhibitor of downstream PI3K was found to effectively 
control metastatic growth of HER2 positive breast cancer cells in multiple organs and 
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resulting in a significant proportion of mice free from brain and bone metastases (Nanni et al, 
2012). In addition, brain metastases of melanoma were shown to have significantly higher 
levels of phosphorylated Akt and lower PTEN than lung or liver metastases (Davies et al, 
2009). This pathway was shown to be activated not only in brain metastatic melanoma cells, 
but also in brain endothelial cells coming in contact with melanoma cell-conditioned media, 
inducing increased endothelial cell proliferation and motility (Anfuso et al, 2009). Moreover, 
the PI3K inhibitor LY294002 was shown to reduce the number of ECM-invading breast 
cancer cells in the presence of pulmonary microvascular endothelial cells (Mierke, 2011). It 
was also shown that melanoma cell-associated VE-cadherin breakdown in human umbilical 
vein endothelial cells (HUVECs) was not sensitive to LY294002, whereas transendothelial 
migration of melanoma cells was reduced in the presence of the PI3K inhibitor (Peng et al, 
2005). However, inhibition of PI3K had no effect on the transmigration of small cell lung 
cancer cells through brain endothelial cells (Li et al, 2006). 
1.3.3.3   Other pathways involved in the interaction of tumor cells with the BBB 
Several other signaling pathways have been shown to influence transendothelial 
migration of metastatic cells. Src signaling is known to participate in many aspects of tumor 
progression and metastasis. It plays an important role in the promotion of mesenchymal and 
inhibition of amoeboid motility (Ahn et al, 2012) and in the phosphorylation of N-cadherin 
and dissociation of β-catenin during transendothelial migration (Qi et al, 2005). 
In melanoma, transforming growth factor-beta 2 (TGF-β2) was found to be crucial, 
since its expression was found indispensable for the formation of parenchymal brain 
metastases (Zhang et al, 2010). Stat3 activation was also found to play an important role in 
angiogenesis, invasion and brain metastasis formation of melanoma cells through 
dysregulated expression of bFGF (basic fibroblast growth factor), VEGF and MMP-2 (Xie et 
al, 2006). VEGF and its receptors may also be involved in the transmigration process. In 
breast cancer cells HER2 increases VEGF protein production, which induces the disruption of 
interendothelial junctions (Fan et al, 2011). In addition, VEGF was shown to increase the 
adhesion of highly metastatic MDA-MB-231 breast cancer cells to brain endothelial 
monolayers and to enhance their transmigration through an in vitro BBB model (Li et al, 
2013). 
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2   Aims 
In our studies we aimed at understanding the mechanisms of transmigration of tumor 
cells through the BBB. We focused on two tumor types with high incidence of brain 
metastasis formation, i.e. melanoma and breast cancer. Breast cancer is the second most 
common cancer type giving cerebral metastases; however, in comparison to melanoma it has a 
much lower propensity to metastasize to the brain. Comparison of the interaction of these two 
different tumor cell types with the cerebral endothelium might help in understanding whether 
the transendothelial migration step of metastasis formation has any role in the higher tropism 
of melanoma cells towards the CNS. In addition, we investigated the impact of Rac, Rho-
ROCK and PI3K signaling on the diapedesis of melanoma and breast cancer cells into the 
brain. Understanding the role of these signaling pathways might lead to the elaboration of new 
preventive and treatment strategies in metastatic diseases of the brain. 
Our investigations had five specific aims: 
1. to compare the transmigration properties of melanoma and breast cancer cells through 
the brain endothelial monolayer under static and dynamic conditions, 
2. to compare the effects of melanoma and breast cancer cells on the tight junctions of 
confluent cerebral endothelial cells, 
3. to understand the role of Rac signaling and of amoeboid vs. mesenchymal phenotype 
in the transmigration of melanoma and breast cancer cells through the BBB,  
4. to investigate the impact of PI3K inhibition on the transmigration of tumor cells 
(melanoma and breast cancer cells) through the cerebral endothelium during brain 
metastasis formation, 
5. to observe the effect of Rac and PI3K inhibitors on the barrier integrity of the brain 
endothelium. 
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3   Materials and methods 
3.1   Cell culture and treatments 
MDA-MB-231 and MCF-7 human breast cancer cells were kept in DMEM medium 
(Sigma) supplemented with 5% FBS (Lonza). A2058 human melanoma cells (obtained from 
the European Collection of Cell Cultures) were maintained in EMEM (Sigma) supplemented 
with 5% FBS (Sigma). A375 human melanoma cells were kept in DMEM medium (Sigma) 
supplemented with 10% FBS (Lonza). 4T1 mouse breast cancer cells were kept in RPMI 
medium (Lonza) supplemented with 5% FBS (Lonza). The hCMEC/D3 human microvascular 
cerebral endothelial cells (abbreviated as D3) (Weksler et al, 2005) were grown on rat tail 
collagen-coated dishes in EBM-2 medium (Lonza) supplemented with EGM-2 Bullet Kit 
(Lonza) and 2.5% FBS (Sigma). Rat brain endothelial cells (RBECs) were used for 
immunofluorescence experiments because of their superior barrier characteristics. Primary rat 
brain endothelial cells (RBECs) were isolated from 2-week old rats. Briefly, after removal of 
meninges cerebral cortices were cut into small pieces and digested with 1 mg/ml collagenase 
type 2 (Sigma). After separation of myelin by centrifugation in 20% bovine serum albumin 
(BSA), a second digestion was performed with 1 mg/ml collagenase/dispase (Roche). 
Microvessel fragments were collected after 10 min 1000•g centrifugation on Percoll (Sigma) 
gradient, and plated onto fibronectin/collagen-coated dishes. Endothelial cells growing out of 
the microvessels were cultured in DMEM/F12 (Life Technologies), 10% plasma-derived 
serum (First Link) and growth factors. In the first two days, 4 µg/ml puromycin was added to 
remove contaminating cells. 
ROCK inhibitors (Y27632, Tocris and fasudil, Santa Cruz) were used in a final 
concentration of 10 μM. EHT1864 (Tocris), an inhibitor of the Rac family GTPases, was 
applied in a 20 µM concentration. LY294002 (Cell Signaling Technology) – a reversible and 
highly selective inhibitor of phosphatidylinositol 3 kinase (PI3K) – was used in a 
concentration of 25 µM. 
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3.2   Adhesion experiments 
Brain endothelial cells (D3) were grown until confluence in 24-well plates. Tumor 
cells (MDA-MB-231, MCF-7, A2058 or A375 cells) were fluorescently labeled using Oregon 
Green 488 carboxylic acid diacetate succinimidyl ester (Life Technologies) using the protocol 
supplied by the manufacturer. 5•104 tumor cells/well were plated onto the endothelial 
monolayer in serum-free medium and incubated for 90 min. Non-attached cells were washed 
and the remaining cells were fixed using ethanol/acetic acid (95/5) at -20°C for 5 min. Tumor 
cells adhered to endothelial cells were photographed and counted using the Image-Pro Plus 
software (Media Cybernetics). 
3.3   Static transmigration experiments using time-lapse video 
imaging 
Human cerebral endothelial cells (D3) were cultured until confluence in 12-well 
plates. 2•104 tumor cells/well were plated onto the endothelial monolayer in Leibovitz’s L-15 
medium (Sigma). Cells were monitored for 6 h using an Andor NEO sCMOS camera 
connected to a Nikon Eclipse Ti-E inverted microscope, equipped with a home built incubator 
set to 37°C. Phase-contrast images were made every 5 min from 5 optical fields/well and 
time-lapse videos were constructed. The movement of each tumor cell was evaluated and 
transmigrated cells were counted. 
3.4   Dynamic transmigration experiments using microfluidics 
3.4.1   Design and fabrication of microdevices 
To investigate the transmigration of tumor cells under low shear stress conditions we 
designed and constructed a biocompatible artificial capillary network. The schematic 
representation of the microfluidic setup is shown in Figure 3. 
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Figure 3. Dynamic transmigration experimental setup: schematic representation of the microfluidic 
device. 
 
The microfluidic capillary device was fabricated from poly-dimethylsiloxane (PDMS, 
Sylgard 184, Dow Corning) using standard photolithography and soft lithography techniques. 
(Qin et al, 2010) Imprints of the microdevices were built by creating 100 µm high SU8-2050 
negative photoresist (MicroChem) layers on silicon wafers. The photoresist layers were 
exposed to UV light through a chromium mask (JD Photo-Tools), using a flood exposure 
source with mask aligner (500W Hg lamp, i-line, model 97435, Newport & Digital Exposure 
Controller model 68945, Newport). In order to prevent the attachment of PDMS to the SU8 
molds, the molds were treated with tridecafluoro-1,1,2,2-tetrahydrooctyl-trichlorosilane 
(Gelest) under vacuum overnight. Positive replicas were fabricated by PDMS molding. The 
PDMS replicas were cured, inlet holes and bubble traps were punched and the devices were 
bound to PDMS-covered microscope glass slides using oxygen plasma treatment. 
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3.4.2   Cell seeding and microfluidic cell culture 
Prior to seeding of brain endothelial cells, the inner surface of the channels was coated 
with rat tail collagen. 106 D3 cells were collected in 100 μl Leibovitz’s L-15 media completed 
with 2.5% FBS (Sigma), growth factor mix (Lonza), hydrocortisone and gentamicin-
amphotericin-B and injected into the microchannels. The microfluidic devices were placed in 
a home built incubator installed on a microscope stage set to 37°C. Cells were kept in “static 
conditions” for 24-36 h to reach a confluent layer. During this static state the medium was 
refreshed every 8 h. When the confluent endothelial layer fully developed, a continuous flow 
of 300 μl/h rate was started and maintained for 24 h to mimic the blood circulation. 
During transmigration experiments, 3•105 tumor cells (A2058 or MDA-MB-231) were 
collected in 100 μl media and injected manually (with syringe). After the injection, a 
continuous flow with 100 μl/h rate was established and maintained for 6 h. Considering the 
physical parameters of the device (channel height of ~100 μm, channel width of ~240-
480 μm) and the used fluid flow rates (100-300 μl/h), we can estimate the shear stress (based 
on Song et al, 2005) acting on the endothelial cells in the microchannels. The applied fluid 
flow generated a low stress regime in our device, in which the shear stress was around ~0.3-
2 dyn/cm2. 
3.4.3   Microscopy 
Phase contrast microscopy images were taken during cell growth and transmigration 
phase, using an Andor NEO sCMOS camera and a Nikon Eclipse Ti-E microscope (Nikon), 
equipped with a 20× Plan Fluor phase contrast objective and a Proscan II motorized 
microscope stage (Prior Scientific). We used the Nikon NIS Elements AR software (Nikon) to 
control the microscope setup during the recordings. Microscopy images were taken every 
30 min during the endothelial cell attachment phase and every 5 min during the 
transmigration experiments (representative images are shown in Figure 4). 
3.5   Immunofluorescence studies 
RBECs were cultured until confluence on collagen/fibronectin-coated filter inserts. 
Tumor cells (MDA-MB-231, A2058 or 4T1) were fluorescently labeled using CellTracker™ 
Red (Life Technologies) and plated onto the endothelial monolayer. After 5 h or 8 h cells were 
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washed and fixed with ethanol/acetic acid. After blocking with 3% BSA, filter inserts were 
incubated with anti-claudin-5 primary antibody (Life Technologies). The staining was 
visualized using Alexa488-conjugated secondary antibody (Jakson Immunoresearch). Nuclei 
were stained with Hoechst 33342 (Sigma). Samples were mounted in FluoroMount-G 
(SouthernBiotech) and studied with a Nikon Eclipse TE2000U microscope connected to a 
digital camera (Spot RT KE, Diagnostic Instruments). 
3.6   Cell viability assay 
Viability of tumor cells and endothelial cells was quantified with the EZ4U non-
radioactive cell proliferation and cytotoxicity assay (Biomedica). D3, A2058, A375, MDA-
MB-231 and MCF-7 cells were seeded in 96-well plates. Next day cells were treated for 5 h 
with 20 μM EHT1864 or 25 μM LY294002 in serum-free, phenol red-free DMEM (Life 
Technologies). After incubation with the EZ4U substrate for 45 min, the absorbance (OD at 
450 nm) was detected using a BMG FLUOstar OPTIMA microplate reader. 
3.7   Wound healing assay 
Tumor cells (MDA-MB-231, MCF-7 or A2058) were seeded into 24-well plates. After 
attachment the cell layer was wounded by scratching with a pipette tip, washed with PBS, and 
exposed to treatments with 20 μM EHT1864 or 25 μM LY294002 in serum-free Leibovitz’s 
L-15 medium. Cells were monitored over 24 h, and phase contrast images were taken every 
30 min with an Andor NEO sCMOS camera connected to the Nikon Eclipse Ti-E inverted 
microscope equipped with a home-built incubator set to 37°C and a 20× Nikon Plan Fluor 
objective, all placed onto a Prior Proscan II motorized stage (Prior Scientific Instruments). 
The wound healing effect was quantified by averaging the number of migrating cells counted 
in five wounded areas. 
3.8   Real-time impedance monitoring 
To monitor the effects of EHT1864 and LY294002 on D3 cells in real-time, we 
measured the electrical impedance using the xCELLigence system following the 
manufacturer’s instructions (Acea Biosciences). Briefly, cells were seeded at a density of 
21 
 
 
 
104 cells/well into 100 μl of media in an E-Plate® (i.e., 96-well tissue culture plates having 
micro-electrodes integrated on the bottom) and allowed to attach onto the electrode surface 
over time. The electrical impedance was recorded every 15 min. When the impedance reached 
plateau (i.e. confluent monolayer with well-formed junctions), the cells were treated with 
20 μM EHT1864 or 25 μM LY294002 for an additional 10 h. The cell impedance (which 
depends on cell number, degree of adhesion, spreading and proliferation of the cells and also 
on the tightness of the junctions), expressed in arbitrary units (cell index), was automatically 
calculated by the software of the instrument. 
3.9   Western-blot analysis 
Confluent D3 brain endothelial cells were treated with 20 μM EHT1864 or 25 μM 
LY294002 for 5 h. Cells were washed with PBS and scraped into ice-cold RIPA buffer 
(20 mM Tris, 150 mM NaCl, 0.5% Triton X-100, 1% sodium deoxycholate, 0.1% sodium 
dodecyl sulphate, 1 mM sodium vanadate, 10 mM NaF, 1 mM 
EDTA/ethylenediaminetetraacetic acid, 1 mM Pefabloc®) and incubated on ice for 30 min. 
Lysates were clarified by centrifugation at 10,000•g for 10 min at 4°C. Proteins were 
electrophoresed and blotted onto nitrocellulose (Bio-Rad) membranes. Blocking was carried 
out at room temperature for 30 min in TBS-T containing 3% BSA. Anti-claudin-5 (Life 
Technologies), primary antibody was used. After washing the membranes in TBS-T (Tris-
buffered saline and Tween 20), blots were incubated with the HRP (horseradish peroxidase)-
conjugated secondary antibody (BD Transduction Laboratories) diluted in TBS-T. The 
immunoreaction was visualized using Clarity ECL Western-Blot Substrate kit (Bio-Rad) in a 
Bio-Rad ChemiDoc MP Imaging System. 
  
22 
 
 
 
4   Results 
4.1   Comparison of the adhesion and transmigration properties of 
breast cancer cells and melanoma cells in vitro 
The first step in the process of brain metastasis formation is the adhesion of tumor 
cells to cerebral CECs. To compare metastatic mammary carcinoma and melanoma cells’ 
adhesion ability we applied an in vitro model of the blood-brain barrier. Since melanoma cells 
have higher propensity to metastasize to the brain than breast cancer cells, we aimed to 
understand whether there is any difference in the interaction of melanoma cells or breast 
cancer cells with the brain endothelium. 
We first aimed to compare the adhesion properties of breast cancer and melanoma 
cells to the brain endothelium. 90 min after plating the tumor cells upon brain endothelial 
cells, significantly more melanoma cells than breast cancer cells were able to attach to the 
endothelium (Table 1). 
 
 
Table 1. Comparison of the adhesion of breast cancer (MDA-MB-231, MCF-7), and melanoma cells 
(A2058, A375) to D3 brain endothelial monolayers. % of plated cells is represented (mean and SD); P 
value was assessed using ANOVA and Bonferroni’s post-hoc test. 
 
Therefore, we wanted to test whether the increased adhesion of melanoma cells in 
comparison to breast cancer cells results in an increased transmigration as well. First, under 
static conditions we studied the transmigration properties of melanoma and breast cancer cells 
and we used a novel in vitro approach based on a time-lapse video setup described in the 
Materials and Methods section. This innovative assay developed in our laboratory makes 
possible to follow the fate of each individual cell in time (adhesion, migration, division, etc.). 
This approach eliminates the drawbacks of assays using filter inserts, where cells migrating 
through the endothelial monolayer but not moving through the pores of the filter cannot be 
considered. Moreover, several cell types (including D3 cells) cannot be properly grown on 
D3+MDA-MB-231 D3+MCF-7 D3+A2058 D3+A375
average 18.44% 18.15% 34.64% 35.05%
st dev 8.66% 8.92% 7.41% 0.75%
p <0.05 vs. A2058 or A375 <0.05 vs. A2058 or A375 <0.05 vs. MDA or MCF <0.05 vs. MDA or MCF
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large pore-size filters due to the formation of a double monolayer on both sides of the 
membrane. 
Comparing the transmigration properties of breast cancer and melanoma cells using 
the static transmigration assay, we observed that fewer breast cancer cells than melanoma 
cells were able to migrate through the brain endothelium (Table 2). The difference was 
significant: 27-28% of plated melanoma cells completed the transmigration process, while 
only 16% of breast cancer cells migrated through. 
 
 
Table 2. Comparison of transmigration of MDA-MB-231, A2058 and A375 cells through D3 brain 
endothelial monolayers under static conditions. % of plated cells is represented (mean and SD); P value 
was assessed using ANOVA and Bonferroni’s post test. 
 
To confirm our results in physiologically more relevant conditions, we constructed a 
dynamic transmigration model. Brain endothelial cells were cultured in a microfluidic device 
(Figure 3; described in details in the Material and Methods section) until confluence (Suppl. 
video 1). After reaching confluence, a slow, physiologically relevant flow of the culture 
medium was initiated (300 µl/h, 1-2 dyn/cm2) for 24 h. Shear stress induced elongation of 
endothelial cells (Figure 4A). This morphological change to fluid shear stress has been 
observed in earlyer studies with different endothelial cells (Dewey et al, 1981). 
After injection of MDA-MB-231 or A2058 cells, the flow was re-started with a rate of 
100 μl/h, phase-contrast images were taken and time-lapse videos were constructed to analyze 
the movements of the tumor cells (Figure 4B, Suppl. video 2 and 3). 
 
 
 
 
 
D3+MDA-MB-231 D3+A2058 D3+A375
average 15.78% 26.99% 28.28%
st dev 0.82% 2.54% 4.72%
p <0.05 vs. A2058 or A375 <0.05 vs. MDA-MB-231 <0.05 vs. MDA-MB-231
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A         a        b 
 
B 
 
Figure 4. Confluent D3 monolayer before (a) and after (b) exposed to continuous flow (A). Dynamic 
transmigration experimental setup: images used for constructing the time lapse videos. D3 cells were 
cultured until confluence in the microfluidic device, exposed to medium flow, then tumor cells were 
injected and left under a continuous flow of 100 µl/h for 6 h. Phase contrast images were taken every 
5 min. Individual tumor cells are marked as follows: white circle = no attachment, black circle = no 
transmigration, white arrow = transmigration in 20 min, black arrow = transmigration in >20 min, black 
box = division. The red dotted stars delineate clusters of transmigrating melanoma cells (B). 
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In these conditions approximately 50% of breast cancer cells and 42.5% of melanoma 
cells showed no attachment and were washed away by the flow of the culture medium in early 
stages of the experiment (Figure 4: white circles, Table 3: no attachment). The percentage of 
tumor cells not washed away from the optical fields studied, but not able to transmigrate in 
6 h, was significantly more in case of breast cancer cells than in case of melanoma cells (15% 
vs. 4.5%, respectively) (Figure 4: black circles, Table 3: no transmigration). Taken together, 
53% of melanoma and 35% of breast cancer cells transmigrated through the brain endothelial 
monolayer in these conditions. The difference in the transmigration between the two cell types 
was the most pronounced in early time points: 23.5% of the total number of melanoma cells 
migrated through the brain endothelium in the first 20 min, while the percentage of breast 
cancer cells transmigrating in this time frame was only 3% (Figure 4: white arrows, Table 3: 
transmigr. in 20 min). 
 
 
Table 3. Comparison of transmigration of A2058 and MDA-MB-231 cells through D3 brain endothelial 
monolayers under dynamic conditions. MDA-MB-231 breast cancer cells or A2058 melanoma cells were 
injected into the microchannels already containing confluent D3 monolayers. Tumor cells were monitored 
for 6 h under a continuous medium flow of 100 μl/h. Tumor cells were divided into four groups: cells 
washed away by the flow of the culture medium (no attachment), cells not transmigrating in 6 h (no 
transmigration), cells migrating through the brain endothelium in the first 20 min (transmigr. in 20 min) 
and cells transmigrating after 20 min (transmigr. in >20 min). % of plated cells is represented (mean and 
SD); P value (comparing D3+MDA-MB-231 and D3+A2058) was assessed with ANOVA and Bonferroni’s 
post-hoc test. 
 
Melanoma cells tended to attach and transmigrate in small groups (Figure 4: red dotted 
star), as we have previously observed in static conditions (Fazakas et al, 2011). After 
transmigration, several melanoma cells continued to move beneath and between endothelial 
cells (as previously seen in static conditions (Fazakas et al, 2011)), sometimes rounding up 
disappearance no transmigration transmigr. in 20 min transmigr. in >20 min
average 50.00% 15.00% 2.80% 32.20%
st dev 4.24% 4.04% 1.73% 3.54%
disappearance no transmigration transmigr. in 20 min transmigr. in >20 min
average 42.50% 4.50% 23.50% 29.50%
st dev 7.21% 1.00% 4.95% 5.12%
p <0.05 <0.05
D3 + MDA-MB-231
D3 + A2058
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and flattening again (Figure 4: cells 1 and 2). A few divisions were also observed (Figure 4: 
black boxes) and the daughter cells usually transmigrated rapidly after division (Figure 4: 
cell 3). Taken together, these results show that melanoma cells are able to adhere to and to 
migrate through the brain endothelium more effectively than breast cancer cells. This might 
be partly responsible for the higher propensity of melanoma cells to metastasize to the brain. 
4.2   Differences in the effects of breast cancer cells and melanoma 
cells on the tight junctions of brain endothelial cells 
We have previously observed that during transmigration melanoma cells are able to 
disrupt the TJs of CECs and use (at least partly) the paracellular way of migration (Fazakas et 
al, 2011). We were interested to understand whether breast cancer cells are also able to impair 
the junctional integrity of the cerebral endothelium. Therefore, we performed claudin-5 
immunostaining on primary rat brain endothelial cell (RBEC) monolayers challenged with 
MDA-MB-231 breast cancer, A2058 melanoma cells, or 4T1 mouse breast cancer cells. We 
have left the tumor cells on the RBEC monolayers for different time intervals (5 h and 8 h). 
As shown in Figure 5, melanoma cells could breach the junctions of RBECs as indicated by 
focal loss of claudin-5 staining. This was not observed in case of breast cancer cells. 
These data suggest that differences in the transendothelial migration of mammary 
carcinoma and melanoma cells might be partly due to differences in their ability to impair 
interendothelial junctions. 
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Figure 5. Effect of breast cancer and melanoma cells on the tight junctions of brain endotheial cells. MDA-
MB-231 human breast cancer cells, A2058 human melanoma cells or 4T1 mouse breast cancer cells 
(labeled in red) were plated onto confluent RBEC monolayers and left for 5 h or 8 h. Tight junctions of 
endothelial cells were stained in green using anti-claudin-5 antibodies. Arrows indicate disappearance of 
claudin-5 staining. 
 
claudin-5 (RBEC) 
Cell Tracker red (MDA/A2058) 
Hoechst (nuclei) 
RBEC+MDA-MB-231 (5 h) 
RBEC+A2058 (5 h) 
RBEC+MDA-MB231 (8 h) 
RBEC+A2058 (8 h) 
RBEC+4T1 (5 h) RBEC+4T1 (8 h) 
100 µm 
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4.3   Effect of Rac or PI3K inhibition on the adhesion of breast cancer 
cells and melanoma cells to the brain endothelium 
The small GTPases Rho and Rac play important role in the movement of tumor cells. 
Rho/ROCK signaling was shown to be involved in the ameboid invasion phenotype of cancer 
cells, which is characterized by rounded morphology and increased actomyosin contractility. 
During mesenchymal type of cell movement, tumor cells gain an elongated morphology, and 
activate extracellular proteolytic mechanisms, and the small GTPase Rac. Tumor cells are 
able to switch between the ameboid and mesenchymal type of cell movement (Symons & 
Segall, 2009). We aimed to understand which mechanism is applied by breast cancer cells 
during transmigration through CECs. We have previously shown that inhibition of the ROCK 
in melanoma cells increases their adhesion to brain endothelial cells. In case of breast cancer 
cells ROCK inhibitors (10 µM Y27632 or 10 µM fasudil) were not able to influence the 
number of breast cancer cells adhering to the brain endothelium (Figure 6A and B). On the 
other hand, the Rac inhibitor EHT1864 (20 µM) hampered the adhesion of both MDA-MB-
231 and MCF-7 breast cancer cells (Figure 6A and B). As expected, mainly the number of 
elongated adherent cells was decreased, which have a mesenchymal phenotype. When both 
ROCK and Rac inhibitors were applied, a similar reduction in the adhesion of tumor cells was 
seen as with the Rac inhibitor alone (Figure 6A). We also observered that the Rac inhibitor 
EHT1864 decreased the number of adherent melanoma cells (Figure 6C).  
In addition, the PI3K inhibitor LY294002 in a concentration of 25 µM significantly 
reduced the number of breast cancer and melanoma cells attaching to the brain endothelium. 
The reduction was approximately 40% compared to control in case of both breast cancer and 
melanoma cells, and mainly affected tumor cells with elongated (flattened, mesenchymal) 
phenotype (Figure 6A,B and D,E). In case of A375 melanoma cells, which presented a 
rounded morphology during adhesion, LY294022 could also significantly reduce the number 
of adherent cells (Figure 6E). 
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Figure 6. Effect of Rac- or PI3K-inhibition on the adhesion of breast cancer cells or melanoma cells onto 
the brain endothelium. Fluorescently labeled MDA-MB-231 (A) or MCF-7 (B) breast cancer cells, A2058 
(C, D) or A375 (E) melanoma cells were plated onto confluent D3 monolayers and left for 90 min. Results 
are expressed as % control and given as mean ± SD. N = 3, ** = P<0.01, * = P<0.05, as assessed by ANOVA 
and Bonferroni’s post-hoc test or Student’s t-test. 
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4.4   Effect of Rac or PI3K inhibition on the transendothelial 
migration of breast cancer cells and melanoma cells in static conditions 
Since inhibition of Rac or PI3K decreased the adhesion of both melanoma and breast 
cancer cells, we tested the effect of Rac or PI3K inhibitors on the transmigration of melanoma 
and breast cancer cells through brain endothelial monolayers as well (Figure 7). In this assay 
we used two invasive melanoma cell lines (A2058 and A375) and the MDA-MB-231 breast 
cancer cell line, which is more invasive than the MCF-7 cell line. Inhibition of Rac with 
EHT1864 significantly reduced the transmigration of both tumor cell types to approximately 
20% in case of breast cancer cells (Figure 7A) and to 15% in case of melanoma cells (Figure 
7C). LY294002 had similar effects: the transmigration percentage was 30% and 40%, 
respectively, compared to control (Figure 7B,D,E). 
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Figure 7. Effect of Rac or PI3K inhibition on the transmigration of breast cancer and melanoma cells 
through the brain endothelium in static conditions. MDA-MB-231 breast cancer cells (A, B), A2058 (C, D) 
or A375 (E) melanoma cells were plated onto confluent D3 monolayers and left for 6 h. Phase-contrast 
images were made every 5 min and transmigrating tumor cells were counted. Results are expressed as % 
control and given as mean ± SD. N = 3, ** = P<0.01, * = P<0.05 as assessed by Student’s t-test. 
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4.5   Effect of Rac or PI3K inhibition on the transendothelial 
migration of breast cancer cells and melanoma cells in dynamic conditions 
Using our dynamic model, we explored which step of transmigration of breast cancer 
or melanoma cells was inhibited by EHT1864 or LY294002. As previously discussed 
(Table 3), only 8% of total transmigrating breast cancer cells completed transmigration in the 
first 20 min (2.8% of 35%), while this was significantly higher in case of melanoma cells 
(44.34%, i.e. 23.5% of 53%). This suggests that melanoma cells can transmigrate more 
rapidly through the brain endothelium than breast cancer cells (Figure 8). Nevertheless, 
EHT1864 and LY294002 inhibited the rapid transmigration of melanoma cells. However, in 
case of breast cancer cells the number of cells transmigrating after 20 min was reduced by 
inhibitors of Rac and PI3K (Figure 8). 
 
 
Figure 8. Effect of Rac or PI3K inhibition on the transmigration of breast cancer cells or melanoma cells 
through the brain endothelium in dynamic conditions. Results are expressed as % control and given as 
mean ± SD. N = 3, * = P<0.05 compared to control, # = P<0.05 A2058 cells compared to MDA-MB-231 
cells, as assessed by ANOVA and Bonferroni’s post-hoc test. 
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Taken together, our results indicate that inhibition of Rac or PI3K impairs the ability 
of both breast cancer and melanoma cells to adhere to and to migrate through the brain 
endothelium. Differences exist however, between the velocities of the transmigration of the 
two tumor cell types. 
4.6   Effects of Rac and PI3K inhibitors on the viability, proliferation 
and migration of tumor cells and brain endothelial cells 
We wanted to exclude that the inhibitory effect of EHT1864 and LY294002 on the 
adhesion and transmigration of breast cancer and melanoma cells was due to toxicity on 
tumor cells. Using the EZ4U assay no toxic effect of either EHT1864 or LY294002 on A2058, 
A375, MDA-MB-231 and MCF-7 cells was observed. Moreover, the EZ4U assay did not 
show any toxicity of EHT1864 or LY294002 on D3 brain endothelial cells (Figure 9). In 
addition, as assessed during the time-lapse video experiments, the number of dividing cells 
was approximately 2.5% in case of MDA-MB-231 cells and 1% in case of A2058 cells. 
Therefore, the observed changes in the adhesion and transmigration are unlikely to be the 
result of an anti-proliferative effect of EHT1864 or LY294002. Moreover, the wound healing 
assay indicated no change in the migratory properties of melanoma or breast cancer cells in 
response to EHT1864 or LY294002 (not shown). 
 
 
Figure 9. Effect of the Rac and PI3K inhibitors on the viability of endothelial and tumor cell lines. 
Viability of the cells was measured using the EZ4U kit. Data are expressed as mean ± SD. 
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4.7   Effect of Rac or PI3K inhibition on the junctional integrity of the 
brain endothelium 
We observed that EHT1864 induced a decrease in the impedance of D3 cells, as 
reflected by the cell index (Figure 10A). After an initial drop induced by the medium change, 
the impedance of control and LY294002-treated D3 cells recovered rapidly. However, in case 
of EHT1864-treated cells the recovery was not complete, and after 5 h a significant drop in 
the impedance was seen. The cell impedance reflects changes in the cell number, viability and 
tightness of the junctions. Since no change in the viability of D3 cells was observed using the 
EZ4U assay, we next investigated the possible damaging effect of the Rac inhibitor on the 
TJs. We observed a significant down-regulation of claudin-5 protein in D3 cells with Western-
blot, in response to EHT1864 (Figure 10B). LY294002 did not significantly affect the amount 
of claudin-5 protein in D3 cells. 
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Figure 10. Effect of the Rac inhibitor EHT1864 and of the PI3K inhibitor LY294002 on the junctional 
integrity of the brain endothelium. Impedance of D3 brain endothelial cells (represented by the cell index) 
was assessed by the ACEA xCELLigence system. Results are expressed as % control and given as mean ± 
SD. N = 3, * = P<0.05 compared to control, as assessed by ANOVA and Bonferroni’s post-hoc test (A). D3 
cells were treated with 20 μM EHT1864 or 25 μM LY294002 for 5 h. Claudin-5 Western-blot was 
performed from the RIPA-soluble fractions. One representative blot and densitometry based on three 
independent experiments is shown. * = P<0.05 compared to control, as assessed by ANOVA and 
Bonferroni’s post-hoc test (B).  
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5   Discussion 
Brain metastases are devastating complications of lung cancer, breast cancer, 
melanoma and other malignancies. Among all solid tumors, melanoma has the highest affinity 
to the CNS. This has been explained by the specific brain environment which supports the 
growth of cells of ectodermal origin (Denkins et al, 2004; Fidler et al, 1999). However, 
besides soluble and cellular elements of the central nervous system, other factors might also 
contribute to the neurotropism of melanoma cells. One of the most important steps in the 
process of brain metastasis formation is the diapedesis of metastatic cells through the barriers 
of the CNS, mainly the BBB-forming microvascular endothelium. The role of the BBB in the 
formation of cerebral metastases is largely unexplored and probably very complex. Being the 
tightest endothelial barrier in the organism, it hinders the transmigration of tumor cells into 
the brain. On the other hand, unique brain endothelial properties might differentially affect the 
diapedesis of different cancer cell types. In order to understand the mechanisms of melanoma 
and breast cancer brain metastasis formation we applied two different in vitro models to study 
the interaction between tumor cells and brain endothelial cells. 
5.1   Model systems used. Comparison of the adhesion and 
transmigration properties of breast cancer and melanoma cells 
The static and dynamic in vitro BBB models used in our experiments are based on the 
culture of hCMEC/D3 (D3) human cerebral endothelial cells. This cell line has been widely 
used as a human BBB model (Carl et al, 2010; Förster et al, 2008), thus this is the most well 
characterized human brain endothelial cell line (Weksler et al, 2013). 
To study the effect of the tumor cells on brain endothelial TJs we used cultures of 
primary rat brain endothelial cells (RBECs). Primary cells in culture maintain the main in 
vivo characteristics of the brain endothelium, i.e. expression of von Willebrand factor, 
presence of a continuous line of TJs, high TEER and low permeability values and high 
activity of P-gp, preserving superior permeability characteristics to cell lines. 
 The time-lapse videos indicated that melanoma cells have increased ability to attach 
to the brain endothelium than breast cancer cells under static and dynamic conditions as well. 
In order to exclude the possibility that this is due to differences in the invasive and metastatic 
capacities between the melanoma and breast cancer cell lines used, we used two different 
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human breast cancer cell lines: the less invasive MCF-7 and the highly migratory and 
metastatic MDA-MB-231 (Wertheimer et al, 2012). We also used two different human 
melanoma cell lines, A2058 and A375, both invasive BRAF V600E mutants, having similar 
propensity to metastasize to different organs (Rozenberg et al, 2010), A2058 being 
vemurafenib resistant, while A375 vemurafenib sensitive (Boussemart et al, 2014). 
The difference between the adhesive properties of melanoma cells and either of the 
breast cancer cell lines was significant. Moreover, such a difference was not observed when 
other endothelial cell types (HUVECs, dermal microvascular cells, lymphatic endothelial 
cells) were used: melanoma cells had similar adhesion properties to non-cerebral endothelial 
cells as breast cancer cells (Safuan et al, 2012). We have also observed a significant difference 
in the number of transmigrating melanoma and breast cancer cells under static and dynamic 
conditions as well. The number of cells not able to migrate through the brain endothelium was 
much higher in case of breast cancer cells than in case of melanoma cells. Moreover, invasive 
melanoma cells tended to complete the transmigration process much more rapidly than 
invasive breast cancer cells.  
The fact that melanoma cells can more easily overcome the BBB may be one of the 
factors leading to the high tropism of melanoma cells towards the CNS. The high proportion 
of brain metastases in melanoma patients has been reported to be a consequence of the so-
called “homing” influence (Denkins et al, 2004), i.e. the ectodermal origin of both 
melanocytes and the CNS. According to our results, the higher ability of melanoma cells to 
impair brain endothelial TJs might also play a role in the higher ability of melanoma cells to 
form brain metastasis in comparison to breast cancer cells. 
5.2   Effect of tumor cells on interendothelial junctions 
Differences between the ability of the two tumor cell types to migrate through the 
brain endothelium might be partly due to their different ability to impair the TJs. 
Our data indicate that melanoma cells are more effective in breaking down the 
paracellular barrier than breast cancer cells. In order to exclude species-specific effects, we 
used both human and mouse breast cancer cell lines. Neither human, nor mouse mammary 
carcinoma cells were able to disrupt the junctions of CECs. On the other hand, human 
melanoma cells induced a time-dependent disappearance of junctional proteins from the 
membranes of brain endothelial cells. Moreover, we have previously shown that mouse 
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melanoma cells (the B16/F10 cell line) had similar effects (Fazakas et al, 2011). Therefore, 
we conclude that melanoma cells are more effective in disrupting the paracellular barrier of 
the brain endothelium than breast cancer cells, independent of species. 
We have previously shown that both breast cancer and melanoma cells are able to 
induce endothelial-mesenchymal transition in CECs (Krizbai et al, 2015), which results in 
loss of junctional integrity. On the other hand, activation of the proteolytic cascade during 
transmigration through the cerebral endothelium seems to be more effective in melanoma 
cells than in breast cancer cells (our unpublished results). Since junctional proteins are targets 
of proteolytic degradation, this difference may be partly responsible for the differences in the 
induction of junctional breakdown. 
On the other hand, breast cancer cells were previously shown to be able to use not 
only the paracellular pathway (through interendothelial junctions), but also the transcellular 
pathway (through the endothelial cell body) during migration through non-cerebral endothelia 
(Arvanitis et al, 2014; Khuon et al, 2010). In this process endothelial myosin light chain 
kinase was activated at the invasion site. 
Our results suggest that breast cancer cells might be more effective in the transcellular 
type of migration than melanoma cells, these latter having increased ability to use the 
paracellular pathway than mammary carcinoma cells. Further analyses will clarify this 
possible difference between the two tumor cell types. 
5.3   Role of Rac and PI3K in the extravasation of tumor cells 
We have also assessed the role of two signaling molecules (Rac and PI3K) in the 
transmigration of melanoma and breast cancer cells through the BBB. In a recent study we 
showed that melanoma cells prefer the Rac-dependent mesenchymal type of cell movement to 
the Rho/ROCK-dependent amoeboid one during transmigration through the BBB. We also 
showed that inhibition of Rac not only impedes the adhesion and transmigration of melanoma 
cells, but of breast cancer cells as well. Interestingly, the ROCK inhibitor Y27632 – which 
significantly facilitated the adhesion of melanoma cells – did not affect the adhesive 
properties of breast cancer cells. This may be the consequence of the very high basal activity 
of the P-Rex1/Rac signaling pathway, which is highly overexpressed in human luminal 
mammary tumors, particularly those expressing HER2 and ER (Wertheimer et al, 2012). 
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The effect of Rac inhibition was similar in case of both melanoma and breast cancer 
cells: a significant decrease in the number of tumor cells attaching to and transmigrating 
through CECs was observed. This supports the idea that inhibition of the mesenchymal 
movement of tumor cells might be beneficial in reducing the diapedesis of different metastatic 
cells through the BBB. Unfortunately, Rac inhibitors – in contrast to ROCK inhibitors, which 
prevent the disruption of the TJs of CECs – might impair the integrity of the BBB.  
The effect of induction of the mesenchymal phenotype on tumor cell motility and 
invasion are contradictory and seem to depend on the tumor cell type. Inhibition of ROCKs 
(i.e. induction of the mesenchymal phenotype) has been shown to decrease the invasion and 
migration of lung (Yang et al, 2012; Yang et al, 2010; Zhu et al, 2011), breast (Wyckoff et al, 
2006), and hepatocellular carcinoma cells (Chen et al, 2011; Itoh et al, 1999; Ying et al, 
2006). In contrast, in case of osteosarcoma (Yui et al, 2010), pancreatic carcinoma (Fujita et 
al, 2011) and colon carcinoma (Adachi et al, 2011; Vishnubhotla et al, 2012), ROCK 
inhibitors improved invasive and migratory properties of the cells. In general, the ameboid 
type of movement appears to more favourable movement for the tumor cells, but this depends 
on the surrounding tissues, properties of the extracellular matrix or the endothelial barrier they 
need to cross (Symons & Segall, 2009). According to our results the mesenchymal phenotype 
seems more effective in case of overcoming the BBB. 
Besides Rac, we tested the role of the PI3K/Akt/PTEN pathway, which is a key 
regulator of tumorigenesis and metastasis formation. BRAF-mutant melanoma cells have been 
shown to have higher levels of pAkt-Ser473, pAkt-Thr308 and decreased expression of PTEN 
(Davies et al, 2009). The A2058 cell line used in our experiments is a V600E BRAF mutant 
expressing high amounts of phosphorylated Akt and low levels of PTEN (Xing et al, 2012). It 
has been shown that inhibition of PI3K results in a reduction of melanoma cell transmigration 
through HUVECs (Peng et al, 2005). Since brain metastases of melanoma have been shown to 
have significantly higher pAkt and lower PTEN levels than extracerebral metastases (Davies 
et al, 2009; Niessner et al, 2013), we aimed to test whether inhibition of this pathway impedes 
the transmigration of melanoma cells through CECs. We observed a marked inhibition of 
melanoma cells able to attach to and to migrate through the brain endothelium in response to 
PI3K inhibition. According to our results, breast cancer cell transendothelial migration could 
be partly blocked using the PI3K inhibitor LY294002 – similarly to melanoma cells. 
The morphology of PI3K-inhibited tumor cells was similar to that of Rac-inhibited 
cells, i.e. we could see a reduction in the number of elongated, flattened cells. This suggests 
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that PI3K inhibition – similar to Rac inhibition – induces an amoeboid-like phenotype in both 
melanoma and breast cancer cells. This is not surprising because PI3K has been shown to 
regulate Rac through P-Rex1 in breast cancer cells (Ebi et al, 2013) and several PI3K lipid 
products have been shown to interact with different RacGEFs (Campa et al, 2015). Moreover, 
a positive feed-back loop exists between P-Rex1 and PI3K (Dillon et al, 2015). 
5.4   Effect of Rac and PI3K inhibitors on the barrier integrity 
Unfortunately, inhibition of Rac impaired the integrity of brain endothelial junctions. 
TJ proteins – which are one of the main elements of barrier properties of CECs – are linked to 
the actin-cytoskeleton and are influenced by small G-proteins. Inhibition of Rho/ROCK 
signaling was shown to prevent disruption of epithelial and endothelial TJs in different 
pathological conditions, e.g. Ca2+-depletion (Samarin et al, 2007; Wilhelm et al, 2007) or HIV 
infection (Xu et al, 2012). We have also observed that ROCK inhibition induces increase of 
TEER in CECs. Although interactions between the two pathways is complex, activation of 
Rho usually leads to inactivation of Rac and vice versa (Burridge & Wennerberg, 2004). 
Therefore, it is not suprising that while inhibition of the Rho/ROCK pathway strengthens the 
junctions, Rac inhibition has an opposite effect. 
In contrast to the Rac inhibitor (EHT1864), the PI3K inhibitor (LY294002) did not 
affect the integrity of the BBB. We observed that EHT1864 decreased the impedance of 
endothelial cells, and we also demostrated a significant down-regulation of claudin-5 protein 
in D3 cells in response to EHT1864, but not in response to LY294002. Many PI3K inhibiting 
agents are in different phases of clinical trials for the treatment of different cancer types 
(Rodon et al, 2013). Based on our results, PI3K inhibitors might turn out to have clinical 
benefits not only in the treatment of primary tumors, but also in preventing brain metastasis 
formation of breast cancer and melanoma. 
 
In conclusion, we have shown that invasive melanoma cells have an increased 
capacity to: 
(1) attach to, 
(2) migrate through and 
(3) impair the tight junctions of  
the brain endothelium than breast cancer cells. 
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In addition, inhibition of Rac or PI3K decreases the number of both melanoma and 
breast cancer cells able to transmigrate through cerebral endothelial cells; however, Rac 
inhibition (but not PI3K inhibition) impairs the junctional integrity of the blood-brain barrier. 
Since inhibitors of the PI3K/Akt pathways are emerging as candidates for anti-cancer therapy, 
the mechanism described here might be of clinical relevance.  
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6   Summary 
Metastatic cells invading the CNS parenchyma have to overcome the blood-brain 
barrier. Tumor cells meet a supportive environment in the brain, protected from 
chemotherapeutics and antitumoral immune response. It is not surprising, therefore, that brain 
metastases of malignant tumors have limited therapeutic options. Hence, it would be of 
crucial importance to prevent the formation of brain metastases. One of the possible strategies 
is to target the step of migration of metastatic cells through the blood-brain barrier. The 
mechanisms of this process are largely uncharacterized. In order to understand these 
mechanisms involved in this process we have used in vitro experimental setups based on the 
culture of cerebral endothelial cells and tumor cell lines.  
We have demonstrated that melanoma cells have enhanced ability of adhesion to and 
transmigration through the brain endothelium than breast cancer cells under static and 
dynamic conditions as well. Moreover, melanoma cells tend to complete the transmigration 
process more rapidly than invasive breast cancer cells.  
Our experiments revealed that melanoma cells are more effective in breaking down the 
tight junctions of cerebral endothelial cells than breast cancer cells. 
Our data indicated that inhibition of Rac impedes the adhesion and transmigration of 
melanoma and breast cancer cells as well. 
We observed a reduction of melanoma and breast cancer cells able to attach to and to 
migrate through the brain endothelium in response to PI3K inhibition. 
In addition, considering their potential therapeutic effects, we have investigated the 
effect of Rac and PI3K inhibitors on the barrier integrity of cerebral endothelial cells. We 
have shown that the Rac inhibitor EHT1864 decreases the amount of junctional protein 
claudin-5, while the PI3K inhibitor LY294002 does not affect the integrity of the BBB. 
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